UroGen Pharma Appoints Elizabeth (Liz) Barrett as President and Chief Executive Officer
UroGen Pharma Ltd. - Ordinary Shares (URGN)
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.urogen.com
Company Research
Source: Business Wire
Ms. Barrett Most Recently Served as CEO for Novartis Oncology and Brings a Track Record of Success in Commercial Oncology NEW YORK--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the appointment of Elizabeth (Liz) Barrett as President and Chief Executive Officer effective immediately. She will also serve on the Company’s Board of Directors. Ms. Barrett, who will be based in New York, replaces Ron Bentsur. Mr. Bentsur will step down from his position at the Company but will continue to serve in an advisory capacity as needed to ensure a smooth transition. Ms. Barrett will present at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2019 at 10:30 a.m. Pacific Time. The event will be held in San Francisco at the W
Show less
Read more
Impact Snapshot
Event Time:
URGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
URGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
URGN alerts
High impacting UroGen Pharma Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
URGN
News
- UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Office Nephrostomy Tube Administration of JELMYTO®, the only Non-Surgical, Kidney-Sparing Treatment for Adults with Low Grade Upper Tract Urothelial CancerBusiness Wire
- UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association Annual MeetingBusiness Wire
- UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2022 Results - Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate DevelopmentsBusiness Wire
- UroGen Pharma Ltd. (<a href="https://www.marketbeat.com/stocks/NASDAQ/URGN/price-target/">NASDAQ: URGN</a>) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.MarketBeat
URGN
Earnings
- 5/10/22 - Beat
URGN
Sec Filings
- 5/10/22 - Form 8-K
- 5/10/22 - Form 10-Q
- 5/3/22 - Form 4
- URGN's page on the SEC website